Equities Analysts Offer Predictions for UNCY Q1 Earnings
by Doug Wharley · The Cerbat GemUnicycive Therapeutics, Inc. (NASDAQ:UNCY – Free Report) – Investment analysts at Brookline Capital Markets issued their Q1 2026 earnings per share estimates for shares of Unicycive Therapeutics in a report released on Tuesday, April 7th. Brookline Capital Markets analyst K. Raja forecasts that the company will post earnings of ($0.32) per share for the quarter. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share. Brookline Capital Markets also issued estimates for Unicycive Therapeutics’ Q3 2026 earnings at ($0.39) EPS, Q4 2026 earnings at ($0.34) EPS, FY2026 earnings at ($1.39) EPS, FY2027 earnings at $5.68 EPS, FY2028 earnings at $4.35 EPS, FY2029 earnings at $5.01 EPS and FY2030 earnings at $2.93 EPS.
Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) last posted its quarterly earnings data on Monday, March 30th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.36).
Several other equities analysts have also recently weighed in on UNCY. Benchmark cut their price objective on Unicycive Therapeutics from $21.00 to $15.00 and set a “speculative buy” rating for the company in a research report on Monday. Guggenheim lowered their price target on Unicycive Therapeutics from $46.00 to $40.00 and set a “buy” rating on the stock in a research note on Thursday, April 2nd. Westpark Capital began coverage on Unicycive Therapeutics in a report on Thursday, February 19th. They issued a “buy” rating for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Unicycive Therapeutics in a report on Friday, March 27th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $25.67.
Check Out Our Latest Analysis on Unicycive Therapeutics
Unicycive Therapeutics Stock Performance
NASDAQ UNCY opened at $6.65 on Friday. Unicycive Therapeutics has a twelve month low of $3.71 and a twelve month high of $11.00. The stock has a market capitalization of $167.83 million, a PE ratio of -3.06 and a beta of 1.81. The stock has a 50-day simple moving average of $6.64 and a 200 day simple moving average of $5.88.
Hedge Funds Weigh In On Unicycive Therapeutics
Large investors have recently added to or reduced their stakes in the company. Lazard Asset Management LLC acquired a new position in Unicycive Therapeutics in the 2nd quarter valued at approximately $55,000. JPMorgan Chase & Co. boosted its stake in Unicycive Therapeutics by 11,698.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock valued at $104,000 after buying an additional 21,525 shares in the last quarter. Quadrature Capital Ltd acquired a new stake in Unicycive Therapeutics in the 4th quarter valued at $226,000. Citadel Advisors LLC acquired a new stake in Unicycive Therapeutics in the 3rd quarter valued at $182,000. Finally, State Street Corp boosted its stake in Unicycive Therapeutics by 19.0% in the 4th quarter. State Street Corp now owns 65,227 shares of the company’s stock valued at $376,000 after buying an additional 10,400 shares in the last quarter. Institutional investors and hedge funds own 40.42% of the company’s stock.
Unicycive Therapeutics Company Profile
Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.